ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Oncology and Hematology News and Journal Articles

Optimizing the Delivery of Antineoplastic Therapies to the Central Nervous System

This review describes the anatomy of the blood-brain barrier and currently available methods to quantify the entry of therapeutic compounds into the brain. It also summarizes data from a variety of approaches designed to improve drug delivery to the central nervous system.

Recent Content

In this interview we discuss prognostic models that may be able to predict disease progression in patients with chronic lymphocytic leukemia treated with the targeted agent ibrutinib.

Combining standard chemotherapy with vadastuximab talirine was safe and well-tolerated in newly diagnosed acute myeloid leukemia.

Administration of bb2121, a novel anti–B-cell maturation antigen CAR T-cell therapy, produced anti-tumor responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to interim data from a phase I trial.

The FDA has approved daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.

As part of our coverage of the ASH Annual Meeting, we are discussing novel agents and strategies for relapsed/refractory Hodgkin lymphoma.

The combination of CB-839, a selective inhibitor of glutaminase, and everolimus seems to have disease activity in patients with advanced renal cell carcinoma.

Gentle reader, the hour is late. As the poet said, almost all of the grains of sand allotted to 2016 have sifted down onto the pyramid of memory. Before this year’s hourglass empties, though, let’s take a moment to reflect on some of the phenomena we observed during the past months in this esoteric branch of medicine.

By clicking Accept, you agree to become a member of the UBM Medica Community.